BCL2L1 and B-cell chronic lymphocytic leukemia: A dominant role of the non-canonical signaling pathway was found and subsequently a pharmacological inhibitor of NIK was applied in order to sensitize CLL cells to venetoclax via downregulation of Bcl-XL.